<div id="readability-page-1"><p>Innate Pharma S.A. Sponsored ADR (NASDAQ:IPHA - Get Free Report)'s stock price fell 2.2% during mid-day trading on Tuesday . The stock traded as low as $1.7612 and last traded at $1.78. 5,402 shares changed hands during mid-day trading, a decline of 73% from the average session volume of 19,733 shares. The stock had previously closed at $1.82.</p><div><p><span></span><span>Get <strong>Innate Pharma</strong> alerts:</span></p></div><h2>Analyst Ratings Changes</h2><p>IPHA has been the subject of a number of recent research reports. BTIG Research  reiterated a &#34;buy&#34; rating and set a $8.00 price objective on shares of Innate Pharma in a research report on Wednesday, October 29th. Weiss Ratings  reiterated a &#34;sell (e+)&#34; rating on shares of Innate Pharma in a report on Thursday, January 22nd. Finally, HC Wainwright  set a $5.00 price objective on shares of Innate Pharma and gave the company a &#34;buy&#34; rating in a research note on Wednesday, October 29th. One research analyst  has rated the stock with a Strong Buy rating, one  has given a Buy rating, one  has issued  a Hold rating and one  has assigned  a Sell rating to the stock. According to MarketBeat, Innate Pharma  has an average rating of &#34;Moderate Buy&#34; and an average price target of $5.00.</p><p><b>Get Our Latest Analysis on IPHA</b></p><h2>Innate Pharma Trading Down 2.2%</h2><p>The company's fifty day moving average price is $1.80 and its two-hundred day moving average price is $1.95. </p><h2>Innate Pharma Company Profile</h2> (Get Free Report)<p>Innate Pharma SA is a clinical-stage biotechnology company specializing in the discovery and development of antibody-based therapies that harness the body's innate immune system to combat cancer. Founded in 1999 and headquartered in Marseille, France, the company pioneers novel monoclonal antibodies designed to activate natural killer cells and macrophages, offering a complementary approach to existing immuno-oncology treatments.  </p><p>The company's lead program, monalizumab, targets the NKG2A immune checkpoint receptor and is being developed in collaboration with AstraZeneca.</p><h2>Recommended Stories</h2><ul><li>Five stocks we like better than Innate Pharma</li><li>The day the gold market broke</li><li>Buy this Gold Stock Before May 2026</li><li>Forget AI, This Will Be the Next Big Tech Breakthrough</li><li>ALERT: Drop these 5 stocks before January 2026!</li><li>Ticker Revealed: Pre-IPO Access to &#34;Next Elon Musk&#34; Company</li></ul><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Innate Pharma Right Now?</h2><p>Before you consider Innate Pharma, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Innate Pharma wasn't on the list.</p><p>While Innate Pharma currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

IBBQ

IPHA

<p>Innate Pharma's stock (NASDAQ:IPHA) fell 2.2% to $1.78 during mid-day trading, with a significant drop in trading volume. Analysts have mixed ratings on the stock, with a "buy" rating from BTIG Research and a price target of $8.00, while Weiss Ratings issued a "sell" rating. The average analyst rating is "Moderate Buy" with a price target of $5.00. The company focuses on developing antibody-based therapies for cancer and is known for its lead program, monalizumab, in collaboration with AstraZeneca.</p>

Innate Pharma (NASDAQ:IPHA) Stock Price Down 2.2% - Should You Sell?